Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy
ReviewHumans
- Design
- Review
- Subjects
- Narrative review
- Dose used in the study
- Up to 1.8 g a day in the trials cited
- Duration
- Not applicable
- What was measured
- The case for palmitoylethanolamide in glaucoma, diabetic retinopathy and uveitis, drawing on the eye trials and the wider trial record
What the authors reported
Palmitoylethanolamide has been tested in at least nine double-blind placebo-controlled studies, two in glaucoma, and found safe and effective up to 1.8 g a day, the authors state. They name the products sold in Italy and the Netherlands for this use.
Limits of this study
A promotional tone: the abstract names commercial products. The lead author runs a clinic that prescribes the compound and has a commercial interest in one product. The glaucoma trials it relies on are small and are listed on this site with their limits.
Source
PubMed 26664738 · doi:10.1155/2015/430596
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.